Roaring Kitty 2.0? Why Grandmaster‐Obi’s $RGC Alert Could Eclipse the GameStop Squeeze

May 12, 2025 | Retail Trading Deep Dive | Short Squeeze Analysis

The retail trading world is buzzing with one question: Is Regencell Bioscience ($RGC) about to out‑squeeze GameStop ($GME)? After Grandmaster‑Obi—former WallStreetBets moderator and lead analyst at the Making Easy Money Stock Market Server on Discord—alerted $RGC at $6.85 on March 13, the stock has sky‑rocketed to an intraday high of $525 today. That’s a 7,566% gain in under two months—yet many believe this is only the beginning.

Below, we unpack why Grandmaster‑Obi’s $RGC call may dwarf Roaring Kitty’s GME saga, layering in real‑time company data, short‑interest metrics, float comparisons, and compounding scenarios that show just how powerful a low‑float retail squeeze can be.

1. From $6.85 to $525: The Anatomy of a 7,566% Rally

• Alert Date: March 13, 2025

• Entry Price: $6.85

• Intraday High (May 12): $525.00

• Gain: +7,566%

On the morning of March 13, Grandmaster‑Obi pinpointed $RGC ( ▲ 32.15% ) as a “textbook gamma‑squeeze candidate”:

His timing was impeccable. Over the next eight weeks, $RGC’s average daily volume exploded from 200,000 shares to 25 million shares, fueling parabolic upside. By today’s session, the stock briefly eclipsed $525—handing early followers astronomical returns.

2. Why $RGC’s Float Makes the Difference

• Low Float, High Volatility: With fewer than 1 million shares available, even a modest uptick in buying interest can send $RGC catapulting—unlike GME’s tens of millions in circulation.

• Short Interest Firestorm: As of May 10, reported short interest in $RGC stood at 65% of float, compared to GME’s 140% during its squeeze. Yet because $RGC’s float is so small, covering that short position requires a fraction of the volume—but produces far steeper price curves.

In short, $RGC’s limited supply magnifies every dollar of buying, creating potential for moves that outstrip GameStop’s iconic rally.

3. Company Profile: Regencell Bioscience (NASDAQ: RGC)

• Industry: Biotechnology / Cell Therapy

• Market Cap: ~$10.5 billion (at $525)

• Float: ~802,140 shares

• Short Interest: ~65% of float

• Insider Ownership: 15% (management & early investors)

• Recent News:

  • April 2025: FDA grants accelerated review for RGC’s flagship regenerative therapy

  • May 2025: Strategic partnership with a leading European biotech for cell expansion technology

Despite fundamental catalysts, the retail‑driven price action has far outpaced any news flow—underscoring the power of a coordinated short‑squeeze play in a tight‑float name.

4. The Morning’s Triple Win: $YHC & $TAOP Alerts

Grandmaster‑Obi’s $RGC ( ▲ 32.15% ) call stole the headlines, but his morning alerts on two other names reminded traders why his server is so coveted:

1. $YHC (YanHua China Holdings)

   • Alerted at $2.83, climbed to $8.70

   • 207.7% gain in under 30 minutes

2. $TAOP (Taoping Inc.)

   • Alerted at $0.20, spiked to $0.67

   • 235% gain within 40 minutes

These velocity trades demonstrate 0bi’s keen eye for short‑interest anomalies and imminent squeezes—factors that preceded each breakout.

5. Compounding the Morning: Turning $1,000 into $5,000+

Traders adept at rolling gains could have turned a small amount into significant profits before 10 AM:

1. $YHC: $1,000 → $3,077

2. $TAOP: $3,077 → $10,332

3. $RGC: $10,332 → $79,000 (using a conservative partial exit at $525)

Total: Approximately +7,800% compound returns—all within the span of a single trading session.

6. Roaring Kitty vs. Grandmaster‑Obi: A Tale of Two Squeezes

• Roaring Kitty (GME, 2021):

  • Narrative‑driven, community‑powered, held long term

  • Peak return ~+1,000% on a much larger float

• Grandmaster‑Obi ($RGC, 2025):

  • Data‑driven, velocity‑focused, tight risk management

  • Peak return ~+7,566% on a micro‑float of <1 million shares

While GME ignited the retail revolution, $RGC’s ultra‑low float and institutional short positioning have created a feedback loop that 0bi triggered with surgical precision—positioning it to outpace GME’s record.

7. Technical Anatomy of the $RGC Squeeze

• Price Channels: Broke above the descending wedge on March 15, followed by a volume surge of 1,200% above average.

• VWAP Tests: Successful retest of the 5‑minute VWAP at $35 in mid‑April signaled strong institutional support.

• Option Open Interest: Call OI on May 10 reached 50,000 contracts expiring within two weeks—a clear sign of aggressive speculative positioning.

Each technical pivot aligned with 0bi’s posted chart levels, enabling server members to enter and scale with confidence.

8. The Broader Context: Why Retail Still Rules Micro‑Caps

• Fed Uncertainty: As rate‑hike fears loom, many small caps become sidelined by institutional managers—creating latent retail opportunities.

• ESG/Healthcare Trends: Biotech remains a favored retail sector—$RGC’s regenerative medicine narrative provided a thematic hook.

• Social Media Amplification: Discord → Reddit → Twitter → Stocktwits formed a cascade of excitement, fueling volume and buy‑side pressure.

In an era of algorithmic trading and passive flows, retail’s agility in micro‑caps like $RGC can trigger genuine market events—not merely frenzied chatter.

9. What Comes Next? Eyes on $420… and Beyond

Grandmaster‑Obi has publicly stated:

With short interest still elevated and float rigidity unchanged, the path to $600 may be paved by the very shorts who attempt to exit at every relief rally.

Analysts caution that “profit‑taking may cause 30–50% retracements,” but in a tight squeeze, those retracements can become fresh fuel for the next leg.

10. Conclusion: Retail’s Squeeze Renaissance

Where Roaring Kitty’s GME run was a singular event, Grandmaster‑Obi’s chain of back‑to‑back short‑squeeze calls—capstone by $RGC’s 7,500% surge—signals a new era of retail influence.

• Micro‑float precision

• Real‑time analytics

• Community amplification

Retail traders no longer need to rely solely on narrative or sentiment. With analysts like 0bi, they have data‑driven signals that can move markets.

As Wall Street recalibrates to this new retail reality, one question remains:

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Always perform your own research and risk analysis before trading.